Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis
Actinic Keratoses
About this trial
This is an interventional treatment trial for Actinic Keratoses
Eligibility Criteria
Inclusion Criteria: Signed informed consent > 18 years of age or older at baseline Fitzpatrick skin type I-III Clinical AKs in two symmetrical areas on the face or on the chest, presented with at least ten AKs Female subjects of childbearing potential must be confirmed not pregnant by negative pregnancy test prior to study inclusion and must use a safe contraceptive method during the study Exclusion Criteria: Previous exposure to PDT, energy-based devices, or AK treatment on the study areas within 3 months Pregnant or lactating women Patients with known allergy to MAL or any ingredients in Cicaplast, Baume B5+ Concomitant treatment with immunosuppressant drugs Infiltrating tumors in the treatment areas Known porphyria Other skin diseases present in the test area at baseline Non-eligibility at the discretion of the investigator (e.g. non-compliance, unavailability or other reasons the subject is not believed to be able to comply with the clinical trial protocol)
Sites / Locations
- Bispebjerg HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Daylight PDT + Cicaplast
Daylight PDT
Pretreatment with currettage. Metvix cream. Daylight PDT. Application of Cicaplast to test area immediately after dPDT. Cicaplast application twce daily for 14 days.
Pretreatment with currettage. Metvix cream. Daylight PDT. No post treatment.